What is HC Wainwright’s Estimate for ZVRA FY2026 Earnings?

by · The Markets Daily

Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Free Report) – Analysts at HC Wainwright raised their FY2026 earnings per share estimates for Zevra Therapeutics in a report released on Wednesday, November 4th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of $0.91 for the year, up from their previous estimate of $0.68. HC Wainwright has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is $0.72 per share. HC Wainwright also issued estimates for Zevra Therapeutics’ Q4 2026 earnings at $0.14 EPS, FY2028 earnings at $0.71 EPS, FY2029 earnings at $1.21 EPS and FY2030 earnings at $1.74 EPS.

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.16 by $0.10. Zevra Therapeutics had a net margin of 52.80% and a return on equity of 54.64%. The firm had revenue of $37.76 million during the quarter, compared to analyst estimates of $37.08 million.

Several other research firms also recently weighed in on ZVRA. William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Canaccord Genuity Group cut their price objective on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating for the company in a research report on Monday, July 27th. Citizens Jmp boosted their price objective on shares of Zevra Therapeutics from $25.00 to $28.00 and gave the company a “market outperform” rating in a research report on Thursday, August 6th. Weiss Ratings restated a “hold (c)” rating on shares of Zevra Therapeutics in a research note on Wednesday, August 19th. Finally, UBS Group reaffirmed a “buy” rating on shares of Zevra Therapeutics in a report on Thursday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $27.14.

Get Our Latest Stock Analysis on ZVRA

Zevra Therapeutics Trading Down 5.7%

ZVRA opened at $10.53 on Friday. The company’s 50 day moving average is $11.07 and its 200 day moving average is $10.77. The company has a market cap of $625.31 million, a price-to-earnings ratio of 8.85 and a beta of 1.01. Zevra Therapeutics has a 12-month low of $8.01 and a 12-month high of $15.03.

Institutional Trading of Zevra Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Fulcrum Asset Management LLP purchased a new position in shares of Zevra Therapeutics in the third quarter valued at about $31,000. Alps Advisors Inc. purchased a new stake in shares of Zevra Therapeutics during the third quarter worth about $528,000. Integrity Alliance LLC. purchased a new stake in shares of Zevra Therapeutics during the third quarter worth about $10,292,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Zevra Therapeutics during the 3rd quarter valued at approximately $33,000. Finally, Profund Advisors LLC raised its position in shares of Zevra Therapeutics by 605.6% during the third quarter. Profund Advisors LLC now owns 109,547 shares of the company’s stock valued at $1,202,000 after buying an additional 94,021 shares during the last quarter. 35.03% of the stock is currently owned by institutional investors.

Insider Activity at Zevra Therapeutics

In other Zevra Therapeutics news, Director Corey Watton sold 12,300 shares of Zevra Therapeutics stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $11.25, for a total transaction of $138,375.00. Following the transaction, the director owned 1,800 shares of the company’s stock, valued at $20,250. The trade was a 87.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Neil F. Mcfarlane sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $11.25, for a total transaction of $225,000.00. Following the completion of the transaction, the chief executive officer owned 417,225 shares of the company’s stock, valued at approximately $4,693,781.25. The trade was a 4.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.70% of the company’s stock.

Zevra Therapeutics Company Profile

(Get Free Report)

Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.

Featured Articles